SCHEMBL12778665

SCHEMBL12778665

Cc1cc(F)n[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21737077 0.72 — —
SCHEMBL3294940 0.71 — —
SCHEMBL1503 0.71 — —
SCHEMBL28959328 0.69 HCAR2 (0.44) —
SCHEMBL29150915 0.69 — —
SCHEMBL30404482 0.69 — —
SCHEMBL28852463 0.69 HCAR2 (0.44) —
Potassium SCHEMBL30471622 0.69 — —
SCHEMBL30802139 0.69 — —
Ammonia Solution, Strong SCHEMBL28254978 0.69 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111542523-B Heterocyclic compounds as PRMT5 inhibitors 朱比连特埃皮斯科瑞有限责任公司 2024-03-29 — — CN disclosed
EP-3611165-B1 PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT MITSUI CHEMICALS CROP & LIFE SOLUTIONS INC (JP) 2023-08-16 — — EP disclosed
WO-2023079291-A1 DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES REDX PHARMA PLC (GB) 2023-05-11 — — WO disclosed
EP-4026834-A1 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE Redx Pharma Plc (GB) 2022-07-13 — — EP disclosed
US-11161862-B2 Phosphonium-ion tethered tetracycline drugs for treatment of cancer OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2021-11-02 — — US disclosed
US-20210087172-A1 FACTOR XIIa INHIBITORS UNIVERSITY OF LEEDS (GB) 2021-03-25 — — US disclosed
CN-111542523-A Heterocyclic compounds as PRMT5 inhibitors 朱比连特埃皮斯科瑞有限责任公司 2020-08-14 — — CN disclosed
US-20200123182-A1 PHOSPHONIUM-ION TETHERED TETRACYCLINE DRUGS FOR TREATMENT OF CANCER RISING TIDE FOUNDATION FOR CLINICAL CANCER RESEARCH (CH) 2020-04-23 — — US disclosed
US-10611766-B2 Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer LOXO ONCOLOGY INC. (US) 2020-04-07 — — US disclosed
EP-3611165-A1 PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT Mitsui Chemicals Agro, Inc. (JP) 2020-02-19 — — EP disclosed
WO-2015140566-A1 PYRAZOLO-PYRIMIDINES AS INHIBITORS OF BTK REDX PHARMA PLC (GB) 2015-09-24 — — WO disclosed
US-20150252019-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. 2015-09-10 — — US disclosed
US-9067929-B2 Heterocyclic compounds and uses thereof CELGENE AVILOMICS RESEARCH, INC. (US) 2015-06-30 — — US disclosed
CN-104684908-A Tetrazolinone compounds and their use as pesticides SUMITOMO CHEMICAL CO 2015-06-03 — — CN disclosed
CN-104684909-A Tetrazolinone compounds and their use as pesticides SUMITOMO CHEMICAL CO 2015-06-03 — — CN disclosed
WO-2015001348-A1 PYRIDAZINE DERIVATIVES AS HEDGEHOG PATHWAY INHIBITORS REDX PHARMA LIMITED (GB) 2015-01-08 — — WO disclosed
WO-2014191736-A1 HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS REDX PHARMA LIMITED (GB) 2014-12-04 — — WO disclosed
WO-2014191737-A1 HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS REDX PHARMA LIMITED (GB) 2014-12-04 — — WO disclosed
US-20140073661-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2014-03-13 — — US disclosed
WO-2011050160-A1 PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME BIOGEN IDEC MA INC. (US) 2011-04-28 — — WO disclosed
Send feedback